Search the Newsreel

Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Earnings Results

Verrica Pharmaceuticals (NASDAQ:VRCA) reported a wider-than-expected adjusted loss of $0.48 per share for the quarter, though revenue slightly exceeded forecasts at $5.86 million. The company saw strong sequential growth in YCANTH dispensed units and net product revenue, and began dosing patients in a pivotal …

Verrica Pharmaceuticals Inc. 2026: Revenue $5.86M, EPS ($0.62) — 10-Q Summary

Verrica Pharmaceuticals Inc. reported a significant decline in its financial performance for the quarter ended 2026, with revenue decreasing by 53.8% to $5.86M and a net loss of ($13.15M), resulting in a diluted EPS of ($0.62). This compares to a net income of $204K …

VRCA|Verrica Pharmaceuticals Inc|Price:5.080|Chg%:-0.280

Verrica secures $27.5 million credit facility from chairman By Investing.com

Verrica Pharmaceuticals Inc. announced a $27.5 million credit facility with an entity controlled by its chairman and largest shareholder, Paul B. Manning. This financing includes an immediate $12.5 million and an additional $15 million upon reaching specific milestones. The funds will support the commercialization …

Is Verrica Pharmaceuticals (VRCA) a Hidden Gem After Q2 Earnings

Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates

Verrica Pharmaceuticals Inc. (VRCA) reported a Q2 loss of $0.48 per share, which beat the Zacks Consensus Estimate of a $0.56 loss, representing a 14.29% surprise. The company's revenues for the quarter were $5.86 million, surpassing estimates by 1.77%, despite being lower than the …

Press Release: Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

Verrica Pharmaceuticals has secured a credit facility of up to $27.5 million with City National Bank, providing non-dilutive growth capital. This financing includes a $20 million term loan and a $7.5 million revolving credit facility. The capital is expected to support the commercial launch …

New funding supports Verrica's global Phase 3 common-warts program

Verrica Pharmaceuticals (Nasdaq: VRCA) has secured a new credit facility of up to $27.5 million in non-dilutive growth capital from an entity controlled by its Chairman, Paul B. Manning. This financing aims to support the commercialization of YCANTH, fund the global Phase 3 common …

YCANTH applicator units reach 19,626; common-wart data expected mid-2027

Verrica Pharmaceuticals reported Q2 2026 total revenue of $5.9 million, down from $12.7 million year-over-year, largely due to the absence of a one-time milestone payment. Despite this, U.S. YCANTH net product revenue grew to $5.1 million, with dispensed YCANTH applicator units increasing by 46.1% …

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results

Verrica Pharmaceuticals Inc. announced its Q2 2026 financial results, reporting a record demand for YCANTH® with 19,626 dispensed applicator units, an increase of 28.3% quarter-over-quarter and 46.1% year-over-year. Total revenue reached $5.9 million, including $5.1 million in U.S. YCANTH net product revenue. The company …

Verrica Pharmaceuticals (VRCA) Projected to Release Quarterly Earnings on Thursday

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

Verrica Pharmaceuticals Inc. announced it will host a conference call and live webcast on Thursday, August 6, 2026, at 4:30 p.m. ET to discuss its second-quarter financial results for the period ending June 30, 2026, and provide a corporate update. Individuals can participate via …

Verrica Sets Aug. 6 Webcast to Discuss Second-Quarter Results

Verrica Pharmaceuticals (Nasdaq: VRCA) announced it will host a conference call and live webcast on August 6, 2026, at 4:30 p.m. ET to discuss its second-quarter 2026 financial results and provide a corporate update. Following this news, VRCA's stock gained 4.05%, trading at $5.39. …

VRCA|Verrica Pharmaceuticals Inc|Price:5.820|Chg%:+0.470

This article provides a comprehensive stock analysis of Verrica Pharmaceuticals Inc (VRCA) by TradingKey. It highlights the company's strong fundamentals and high growth potential, despite a recent weak stock market performance. The analysis also covers its valuation, institutional ownership, analyst ratings, and details about …

Verrica Pharmaceuticals Inc (VRCA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Verrica Pharmaceuticals Inc (VRCA), listing its major individual and institutional holders, including Manning (Paul B.) and BKB Growth Investments LLC. It also breaks down shareholder types, such as individual investors, corporations, and hedge funds, and provides a …

TradingKey

This article provides a detailed quarterly and annual income statement for Verrica Pharmaceuticals Inc. (VRCA), from FY2017Q1 through FY2026Q1, including metrics like total revenue, operating expenses, R&D expenses, operating profit, and net income. It also includes frequently asked questions about interpreting income statements and …

Verrica Pharmaceuticals Inc (VRCA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Verrica Pharmaceuticals Inc (VRCA)'s dividend history and stock split events. It states that the company has not distributed any dividends in the past five years and details a merger stock split event scheduled for July 23, 2025. The …

Verrica Pharmaceuticals Inc (VRCA) Valuation: PE, PB & Fair Value Analysis

Verrica Pharmaceuticals Inc (VRCA) currently holds a valuation score of 7.40, placing it 129th out of 155 companies in the Pharmaceuticals industry. The company's P/E ratio stands at -4.84, which is significantly below its recent high and above its recent low. Key financial metrics …

Verrica Pharmaceuticals Inc (VRCA) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Verrica Pharmaceuticals Inc (VRCA), noting its current risk score of 1.60 within the Pharmaceuticals industry. The company's beta value of 1.52 indicates higher volatility compared to the S&P 500. The assessment details various metrics including VaR, maximum …

Verrica Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:VRCA

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) reported significant revenue growth last year, generating $35.58 million USD, primarily from its Novel Topical Solution of Cantharidin segment. This represents a substantial increase from $7.57 million USD in the previous year, with all revenue originating from the United States. …

Verrica grants Medomie exclusive rights for YCANTH in Israel

Verrica Pharmaceuticals Inc. has granted Medomie Pharma Ltd. exclusive distribution, marketing, and supply rights for its drug YCANTH in Israel. The agreement allows Medomie to seek regulatory approval and distribute YCANTH for the treatment of molluscum contagiosum, with Verrica manufacturing and supplying the product. …

Verrica deal could bring YCANTH to Israeli children if approved

Verrica Pharmaceuticals has signed an exclusive distribution, marketing, and supply agreement with Medomie Pharma to commercialize YCANTH for molluscum contagiosum in Israel. While Medomie will seek regulatory approval and distribute the product, Verrica will manufacture and supply YCANTH, receiving 60% of the net selling …

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

Verrica Pharmaceuticals and Medomie Pharma have entered an exclusive distribution, marketing, and supply agreement to commercialize YCANTH® for molluscum contagiosum in Israel. Medomie will seek regulatory approval and distribute the product, while Verrica manufactures YCANTH and receives 60% of net sales, plus up to …